avandia

Did GlaxoSmithKline's blockbuster diabetes drug Avandia cause fatal heart attacks? The first federal trial of an Avandia lawsuit began this morning in Philidelphia. As many as 50,000 more lurk in the wings.

GlaxoSmithKline Plc agreed to pay $750 million to settle charges that the drug making giant sold contaminated anti-nausea medication and baby ointment made at a now-closed Cidra plant in Puerto Rico.

GlaxoSmithKline's Avandia diabetes drug got hit with a double whammy from regulators on both sides of the pond Thursday. The European Medicines Agency announced plans to yank the drug from the market in the coming months, while U.S. officials placed greater restrictions on its use.

GlaxoSmithKline's diabetes drug Avandia should remain on the market but with new restrictions due to possible heart risks, says a federal panel of health experts. The U.S. Food and Drug Administration advisers voted 20-12 to keep the medicine available -- 10 panelists also recommended limiting who...

GlaxoSmithKline's (GSK) shares climbed 2.2% in pre-market trading after a majority of the U.S. Food and Drug Administration's panel voted to keep its controversial type 2 diabetes drug Avandia on the U.S. market, albeit with new restrictions. The diabetes drug already carries a black box label...

GlaxoSmithKline diabetes drug Avandia has been found to have increased heart attack risk compared to similar medication. But a majority of the Food and Drug Administration's panel of outside experts have voted to keep the drug on the market -- though new restrictions are likely.

GlaxoSmithKline, whose diabetes drug Avandia is undergoing a safety review by the FDA, has agreed to pay about $460 million to resolve about 10,000 lawsuits from users of the drug, which can allegedly cause heart attacks and strokes.

Drug maker GlaxoSmithKline intentionally hid the risks of its diabetes drug Avandia and promoted it despite its potential to increase incidents of heart attack, a U.S. Senate committee says in a report to the U.S. Food and Drug Administration. The FDA is holding a special two-day meeting today and...

On Tuesday, the FDA will convene a panel of experts to discuss GlaxoSmithKline's type II diabetes drug Avandia. Once a blockbuster, sales of the drug have dropped by more than half since studies suggested it significantly increases risk for serious heart problems.

Problems for GlaxoSmithKline just seem to be getting worse. The European Medicines Agency said Friday it's launching a new review of Avandia's benefit-risk profile following new data on the possibility of cardiovascular complications.